USANA Health Sciences, Inc. (NYSE:USNA) Issues Quarterly Earnings Results
USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Tuesday. The company reported $0.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.08, Bloomberg Earnings reports. The firm had revenue of $257.10 million during the quarter, compared to the consensus estimate of $273.61 million. USANA Health Sciences had a return on equity of 31.84% and a net margin of 9.71%. The firm’s revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.07 EPS. USANA Health Sciences updated its FY17 guidance to $3.50-3.70 EPS.
Shares of USANA Health Sciences (USNA) traded up 1.49% during mid-day trading on Tuesday, hitting $64.75. The stock had a trading volume of 117,399 shares. USANA Health Sciences has a 52-week low of $52.55 and a 52-week high of $75.00. The stock’s 50-day moving average price is $64.22 and its 200-day moving average price is $60.96. The firm has a market cap of $1.59 billion, a PE ratio of 16.35 and a beta of 1.13.
USNA has been the subject of several analyst reports. Zacks Investment Research raised USANA Health Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, April 12th. Pivotal Research reissued a “hold” rating and issued a $55.00 price objective (down from $75.00) on shares of USANA Health Sciences in a research note on Monday, May 1st. Finally, BidaskClub raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday, June 13th.
In other news, Director Gilbert A. Fuller sold 4,884 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The stock was sold at an average price of $64.38, for a total value of $314,431.92. Following the sale, the director now directly owns 4,884 shares of the company’s stock, valued at approximately $314,431.92. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Myron W. Wentz sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $64.15, for a total value of $2,566,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,735 shares of company stock worth $8,371,021. Insiders own 53.20% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.